Cargando…
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients
Antioestrogen treatment by tamoxifen is a well-established adjuvant therapy for oestrogen receptor-alpha (ERα) positive breast cancer. Despite ERα expression some tumours do not respond to tamoxifen and we therefore delineated the potential link between the cell cycle regulator and ERα co-factor, cy...
Autores principales: | Stendahl, M, Kronblad, Å, Rydén, L, Emdin, S, Bengtsson, N O, Landberg, G |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409465/ https://www.ncbi.nlm.nih.gov/pubmed/15138475 http://dx.doi.org/10.1038/sj.bjc.6601831 |
Ejemplares similares
-
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment
por: Michalides, R, et al.
Publicado: (2002) -
Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray
por: Hedberg, Y, et al.
Publicado: (2003) -
Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence
por: Jirström, K, et al.
Publicado: (2003) -
Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance
por: Luo, L-Y, et al.
Publicado: (2002) -
The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer
por: Kaas, R, et al.
Publicado: (2003)